Treeline Biosciences Holdings Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 169

Employees

  • Latest Deal Type
  • Reverse Merger
  • (Announced)

  • Investors
  • 14

Treeline Biosciences Holdings General Information

Description

Treeline Biosciences Holdings Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and other serious diseases. Its clinical-stage pipeline includes three Phase 1 programs, TLN-121, TLN-254, and TLN-372, and a fourth program, TLN-499, which is nearing clinical entry, all focused on oncology. Its preclinical pipeline includes programs in neurology, immunology, and oncology.

Contact Information

Formerly Known As
JHB Explorations
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 500 Arsenal Street
  • 2nd Floor
  • Watertown, MA 02472
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 500 Arsenal Street
  • 2nd Floor
  • Watertown, MA 02472
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Treeline Biosciences Holdings Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Reverse Merger 20-Jul-2026 Announced Clinical Trials - Phase 1
3. Early Stage VC (Series A) 01-Sep-2025 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A1) 11-Oct-2022 $261M $473M Completed Clinical Trials - General
1. Early Stage VC (Series A) 09-Apr-2021 $212M $212M Completed Clinical Trials - General
To view Treeline Biosciences Holdings’s complete valuation and funding history, request access »

Treeline Biosciences Holdings Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A
To view Treeline Biosciences Holdings’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Treeline Biosciences Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Treeline Biosciences Holdings Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for oncolo
Drug Discovery
Watertown, MA
169 As of 2026

San Diego, CA
 

Framingham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Treeline Biosciences Holdings Competitors (76)

One of Treeline Biosciences Holdings’s 76 competitors is Kura Oncology, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kura Oncology Formerly VC-backed San Diego, CA
Xenetic Biosciences Corporation Framingham, MA
Pharmacyclics Venture Capital-Backed San Francisco, CA
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 76 competitors. Get the full list »

Treeline Biosciences Holdings Patents

Treeline Biosciences Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026183534-A1 2-cyclopropyl-3,3,9-trifluoro-l,2,3,4-tetrahydro- [1,4|oxazepino[2,3-ciouinolin-6(7h)-one bcl6 modulators Pending 28-Feb-2025
WO-2026183536-A1 Bcl6 bifunctional degraders and methods and intermediates for synthesizing the same Pending 28-Feb-2025
WO-2026183449-A1 Methods for treating cancer including a heterobifunctional degrader of bcl6 Pending 28-Feb-2025
WO-2026183523-A1 Methods for treating cancer including a heterobifunctional degrader of bcl6 Pending 28-Feb-2025
WO-2026178027-A1 Spirocyclic dihydropyranopyrimidine kras inhibitors Pending 18-Feb-2025 C07D519/00
To view Treeline Biosciences Holdings’s complete patent history, request access »

Treeline Biosciences Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Treeline Biosciences Holdings Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Exor PE/Buyout Minority
Fidelity Corporation Minority
Rock Springs Capital Venture Capital Minority
Access Industries PE/Buyout Minority
Aisling Capital Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Treeline Biosciences Holdings Acquisitions (1)

Treeline Biosciences Holdings’s most recent deal was a Merger/Acquisition with Standard BioTools. The deal was made on 08-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Standard BioTools 08-Jun-2026 Merger/Acquisition Discovery Tools (Healthcare)
To view Treeline Biosciences Holdings’s complete acquisitions history, request access »

Treeline Biosciences Holdings FAQs

  • When was Treeline Biosciences Holdings founded?

    Treeline Biosciences Holdings was founded in 2021.

  • Where is Treeline Biosciences Holdings headquartered?

    Treeline Biosciences Holdings is headquartered in Watertown, MA.

  • What is the size of Treeline Biosciences Holdings?

    Treeline Biosciences Holdings has 169 total employees.

  • What industry is Treeline Biosciences Holdings in?

    Treeline Biosciences Holdings’s primary industry is Drug Discovery.

  • Is Treeline Biosciences Holdings a private or public company?

    Treeline Biosciences Holdings is a Private company.

  • What is Treeline Biosciences Holdings’s current revenue?

    The current revenue for Treeline Biosciences Holdings is .

  • How much funding has Treeline Biosciences Holdings raised over time?

    Treeline Biosciences Holdings has raised $1.09B.

  • Who are Treeline Biosciences Holdings’s investors?

    Exor, Fidelity, Rock Springs Capital, Access Industries, and Aisling Capital are 5 of 14 investors who have invested in Treeline Biosciences Holdings.

  • Who are Treeline Biosciences Holdings’s competitors?

    Kura Oncology, Xenetic Biosciences, Pharmacyclics, NGM Biopharmaceuticals, and Sarepta Therapeutics are some of the 76 competitors of Treeline Biosciences Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process